机构地区:[1]Provincial Key Laboratory of TCM Diagnostics,Hunan University of Chinese Medicine,Changsha,Hunan 410208,China [2]Department of Cardiology,The Hunan Brain Hospital,Changsha,Hunan 410007,China [3]Center for Oral/Head & Neck Oncology Research,School of Dentistry,University of California,Los Angeles,California 90095,USA [4]Department of Traditional Chinese Medicine,Luohu District People's Hospital,Shenzhen,Guangdong 518001,China
出 处:《Digital Chinese Medicine》2019年第2期86-96,共11页数字中医药(英文)
基 金:the funding support from the National Natural Science Foundation of China (No. 81373551);Hunan Natural Science Foundation (No. 2019JJ40214);Hunan Provincial Health and Family Planning Commission (No. 20190638);Hunan Provincial Brain Hospital (No. 2018B07);Innovation of Graduate Students in Hunan University of Traditional Chinese Medicine (No. 2018CX05 and No. 2018CX25);Postgraduate Innovation in Hunan Province (No. CX20190536 and No. CX20190591)
摘 要:Objective To investigate the potential molecular mechanism of Xin Hui Tong Formula (XHTF) in the treatment of coronary heart disease (CHD) by using network pharmacology and bioinformatics. Methods The targets network of CHD was constructed through Therapeutic Targets Database (TTD) and Drugbank database;The XHTF pharmacodynamic molecule-targets network and the XHTF pharmacodynamic molecule-CHD targets network were explored by the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). And the multi-targets mechanism and molecular regulation network of XHTF in the treatment of CHD were explored from multiple perspectives by Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) database pathway enrichment analysis. Results A total of 88 CHD targets were screened out through the Therapeutic Targets and the Drugbank database. 393 compounds and corresponding 205 drug targets of XHTF were retrieved from TCMSP. A total of 13 known targets directly related to the development of CHD were retrieved from the disease-related databases: TP53, MAPK14, NFKB1, HSPA5, PLG, PTGS2, ADRB1, NOS2, CYP3A4, GRIA2, CYP2A6, GRIA1, PTGS1. XHTF also contained 118 drug targets that directly interact with CHD targets. GO enrichment analysis showed that the biological processes of 13 direct targets proteins were found to be mainly enriched in response to drug, cellular response to biotic stimulus, long-chain fatty acid metabolic process, fatty acid metabolic process and regulation of blood pressure. KEGG pathway enrichment analysis found that XHTF participated in the CHD pathological process mainly through retrograde endocannabinoid signaling, regulation of lipolysis in adipocytes, cAMP signaling pathway, chemical carcinogenesis and other pathways. Conclusions XHTF plays a role in the treatment of CHD through multiple targets and multiple pathways, and provides a scientific basis for the theory of "virtual standard" in the treatment of CHD.目的采用网络药理学和生物信息学方法,研究心惠通方(XHTF)治疗冠心病可能的分子机制。方法通过Therapeutic Target Database, Drugbank 等构建冠心病的靶点网络, TCMSP 挖掘XHTF 药效分子-靶点网络及XHTF 药效分子-冠心病靶点网络,采用GO 分析及KEGG 通路富集分析工具从多个角度探索XHTF 治疗冠心病的多靶点作用机制和分子调控网络。结果利用TherapeuticTargets Database 及Drugbank 数据库共获得88 个冠心病的靶点。从TCMSP 数据库检索到XHTF393 个化合物以及对应的205 个药物靶点;通过相关数据库共检索到XHTF 可直接作用于13 个冠心病的靶点,分别为: TP53、MAPK14、NFKB1、HSPA5、PLG、PTGS2、ADRB1、NOS2、CYP3A4、GRIA2、CYP2A6、GRIA1、PTGS1。同时,XHTF 还含有118 个与冠心病疾病靶点直接相互作用的药物靶点。通过GO 分析发现13 个直接靶点蛋白的生物学过程主要富集在药物反应,生物刺激的细胞反应,长链脂肪酸的代谢过程,脂肪酸代谢过程,血压调控等。KEGG 通路富集分析发现心惠通直接作用冠心病的通路主要包括cAMP 信号通路、调节脂肪细胞中的脂肪分解等信号通路。结论心惠通方可通过多靶点、多途径发挥防治冠心病的作用,其主要与调节能量代谢、抗凋亡、抗氧化应激等途径相关,为进一步探讨其药效物质基础分析和作用机制研究提供了依据。
关 键 词:Xin Hui Tong Formula (XHTF) Coronary heart disease Network pharmacology Network analysis BIOINFORMATICS
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...